SOLA Pharmaceuticals

What SOLA Pharmaceuticals does

SOLA Pharmaceuticals, Inc. is a privately held pharmaceutical manufacturer and distributor headquartered in Baton Rouge, Louisiana. Founded in 2015, the company develops and markets a portfolio of FDA-approved, cGMP-manufactured prescription (RX) generics and over-the-counter (OTC) products spanning NSAIDs, topical analgesics, muscle relaxants, injectables, ophthalmics, and specialty medications such as multiple sclerosis therapies. Its technology focus is on extended topical dosage forms (creams, ointments, gels, lotions, patches) alongside tablets, capsules, sterile injectables, and ophthalmic solutions, with branded OTC sub-lines including Coxanto, LenzaPro, Synoflex, Neuracin, Triceptin, and Capsimide.

The company operates an integrated model combining manufacturing oversight with a state-licensed, FDA-registered, cGMP-certified, and DSCSA-compliant distribution facility in Baton Rouge, augmented by internal logistics that deliver nationwide in the US. It serves two primary B2B channels: independent retail pharmacies seeking reliable generic supply, and large hospital systems requiring consistent, compliant pharmaceutical inventory. The company is NABP-accredited and has expanded into Canada via dedicated English and French market websites and a Canada operations office.

Revenue is generated through product sales to healthcare providers and pharmacies, with a one-time / unit-sale model. Patient access is supported through the SolaLOYALTY Co-Pay Card program — administered in partnership with pharmacy benefit manager Drexi — which enables eligible patients to pay as little as $0 per fill on medications such as Ibuprofen 300mg. SOLA's competitive positioning rests on regulatory compliance, integrated distribution, and patient access infrastructure rather than novel molecular development.

Name

SOLA Pharmaceuticals

Legal name

SOLA Pharmaceuticals, Inc.

Website

https://solameds.us

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

SOLA Pharmaceuticals is a Baton Rouge-based private pharmaceutical manufacturer and distributor that develops FDA-approved, cGMP-certified generic prescription and OTC products — including topicals, injectables, tablets, and ophthalmics — and supplies them to independent pharmacies and hospital systems across the United States and Canada.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

OTC Medicines & Consumer Health Products Distribution (CRAOAHAB)

akta.pro secondary industries

Prescription Pharmaceutical (Rx) Wholesale Distribution (CRAOAHAA), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Ophthalmic & Otic Generics (HLAIABAF), Allergy, Sinus & Respiratory (Non-Asthma) (HLAIADAC)

Keywords

• Generic pharmaceuticals
• Topical medications
• Injectable medications
• OTC analgesics
• Prescription drugs

Headquarters

HQ city

Baton Rouge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Infrastructure, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: SOLA generates revenue through the manufacture and sale of prescription (RX) and over-the-counter (OTC) pharmaceutical products including topical medications, injectables, patches, and tablets to healthcare providers and pharmacies across the United States.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

SOLA Pharmaceuticals manufactures and distributes a portfolio of generic prescription (RX) and over-the-counter (OTC) pharmaceutical products, with a focus on topical medications (creams, ointments, gels, lotions, and patches), injectables, tablets, capsules, and ophthalmic solutions. Products are manufactured at FDA-approved, cGMP-certified facilities and distributed nationwide from the company's Louisiana-based facility to independent pharmacies and hospital systems. The company supports patient access through the SolaLOYALTY Co-Pay Card program.

Product overview

SOLA Pharmaceuticals is a pharmaceutical manufacturer that develops and markets high-quality prescription (RX) and over-the-counter (OTC) products. The portfolio spans multiple therapeutic categories including topical medications (creams, ointments, gels, lotions, and patches), injectables, tablets, capsules, and ophthalmic solutions. The company focuses on generic formulations that serve as alternatives to branded reference products (e.g., Lioresal, Dostinex, Voltaren, Flexeril). Key product lines include NSAIDs (Diclofenac, Ibuprofen, Oxaprozin, Ketorolac), topical analgesics (Lidocaine, Capsimide, LenzaPro, Synoflex, Neuracin, Triceptin), specialty medications (Dimethyl Fumarate, Teriflunomide for MS), injectables (Carboprost, Ketorolac, Ropivacaine, Cyanocobalamin, Saline Bags), and ophthalmic products (Ofloxacin, Olopatadine, Phenylephrine, Ketorolac Ophthalmic). The company supports patient access through the SolaLOYALTY Co-Pay Card program. All products are manufactured at FDA-approved, cGMP-certified facilities and distributed from the company's Louisiana-based facility.

Differentiator

Problem solved

Functional benefit

Brands

• SolaLOYALTY: Co-pay card program for prescription savings on eligible medications
• Coxanto
• LenzaPro Flex Patch
• Neuracin Gel
• Synoflex Patches
• Triceptin Topical Patch
• Capsimide

Products and services

• Baclofen Tablets, USP (RX)

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Drexi, Inc. (d/b/a Drexi)coreChannel Partner/ Reseller/ DistributorDrexi, Inc. serves as the Administrator of the SolaLOYALTY Card Program, a pharmacy benefit manager handling copay assistance program administration. The partnership enables eligible patients to pay as little as $0 per fill for covered medications through participating pharmacies. The program uses BIN #017290 for claims processing via NCPDP standards.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• Amneal Pharmaceuticals: US-focused generic and specialty pharmaceutical company with a broad multispecialty portfolio including injectables, topicals and ophthalmics distributed through retail pharmacy and hospital channels.
• Apotex: Canadian-headquartered generic pharmaceutical manufacturer with established US operations, offering a comparable Rx/OTC generics portfolio and direct pharmacy distribution — particularly relevant given SOLA's Canadian expansion.
• Upsher-Smith Laboratories: Mid-sized US generics and specialty pharmaceutical manufacturer serving retail pharmacies and hospital systems with a comparable mix of generic Rx, OTC and specialty products.
• ANI Pharmaceuticals: US-based specialty generics and branded pharmaceutical manufacturer of approximately comparable scale, with a similarly diversified portfolio of generic Rx and specialty products targeted at pharmacies and hospital systems.
• Padagis: Specialty generics and OTC topical pharmaceutical company with a particularly strong topical analgesics franchise (lidocaine patches, creams, ointments), closely mirroring SOLA's topical pain-relief positioning and pharmacy-channel distribution model.

Broad incumbents

• Aurobindo Pharma USA: Vertically integrated generics major with growing US presence across oral solids, injectables and ophthalmics; competes with SOLA on many of the same molecules at significantly lower COGS.
• Glenmark Pharmaceuticals: India-headquartered global generics manufacturer with a US subsidiary marketing branded and generic dermatology/topical products, overlapping with SOLA's pain-relief and topical franchise.
• Teva Pharmaceutical Industries: Largest US generic manufacturer by volume, with deep OTC and topical analgesic exposure; represents the dominant price- and shelf-share benchmark that smaller generic houses like SOLA must compete against.
• Sandoz (Novartis): World's largest pure-play generics and biosimilars manufacturer with substantial presence across oral solids, injectables, topicals and dermatology — competes with SOLA on most molecules in their portfolio but at vastly greater scale.
• Hisamitsu Pharmaceutical (Salonpas): Japanese pharmaceutical company and owner of the Salonpas brand that SOLA directly references for its capsaicin Capsimide patch — the dominant OTC topical pain patch incumbent against which SOLA competes for shelf space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sola-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SOLA Pharmaceuticals